{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:39:21Z","timestamp":1760575161932,"version":"build-2065373602"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ejps.2019.105122","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T20:05:01Z","timestamp":1572725101000},"page":"105122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7952-846X","authenticated-orcid":false,"given":"Jean-Marie","family":"Nicolas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugues","family":"Chanteux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Nicola\u00ef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Brouta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Viot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Luce","family":"Rosseels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Gillent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Bonnaillie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois-Xavier","family":"Mathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Helmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2019.105122_bib0002","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1124\/jpet.116.237347","article-title":"Seletalisib: characterization of a novel, potent, and selective inhibitor of PI3Kdelta","volume":"361","author":"Allen","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Suppl 3","key":"10.1016\/j.ejps.2019.105122_bib0003","first-page":"S11","article-title":"Loperamide: a pharmacological review","volume":"7","author":"Baker","year":"2007","journal-title":"Rev. Gastroenterol. Disord."},{"key":"10.1016\/j.ejps.2019.105122_bib0004","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/sj.bjp.0705721","article-title":"Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice","volume":"141","author":"Barraud de Lagerie","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105122_bib0005","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/cpt.1402","article-title":"Imaging P-Glycoprotein function at the blood-brain barrier as a determinant of the variability in response to central nervous system drugs","volume":"105","author":"Bauer","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105122_bib0006","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.13301","article-title":"Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[11 C]verapamil in elderly vs. young subjects.","author":"Bauer","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105122_bib0007","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/clpt.2011.217","article-title":"Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data","volume":"91","author":"Bauer","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105122_bib0008","first-page":"1210","article-title":"Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K\/mTOR inhibitor in a mouse model of glioblastoma","volume":"17","author":"Becker","year":"2015","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ejps.2019.105122_bib0009","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF01062191","article-title":"Physiologic modeling of cyclosporin kinetics in rat and man","volume":"19","author":"Bernareggi","year":"1991","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejps.2019.105122_bib0010","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/jat\/bkw069","article-title":"Loperamide-Related deaths in North Carolina","volume":"40","author":"Bishop-Freeman","year":"2016","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.ejps.2019.105122_bib0011","series-title":"Comprehensive Medicinal Chemistry III","first-page":"366","article-title":"8.15 - The discovery and development of seletalisib: a potent and selective PI3K\u03b4 inhibitor for inflammatory diseases A2 - Chackalamannil, Samuel,","author":"Brookings","year":"2017"},{"key":"10.1016\/j.ejps.2019.105122_bib0012","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1021\/jm300241b","article-title":"Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kbeta inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers","volume":"55","author":"Certal","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2019.105122_bib0013","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/dmd.116.073890","article-title":"Application of static modeling \u2013in the prediction of in vivo drug-drug interactions between rivaroxaban and antiarrhythmic agents based on in vitro inhibition studies","volume":"45","author":"Cheong","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.105122_bib0014","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.xphs.2017.06.014","article-title":"An investigation of oral exposure variability and formulation strategy: a case study of PI3Kdelta inhibitor and physiologically based pharmacokinetic modeling in beagle dogs","volume":"107","author":"Chiang","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105122_bib0015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/17425255.2013.741589","article-title":"Species differences in drug transporters and implications for translating preclinical findings to humans","volume":"9","author":"Chu","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejps.2019.105122_bib0016","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10928-013-9301-9","article-title":"Utility of CSF in translational neuroscience","volume":"40","author":"de Lange","year":"2013","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2019.105122_bib0017","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejps.2018.08.022","article-title":"P-glycoprotein protein expression versus functionality at the blood-brain barrier using immunohistochemistry, microdialysis and mathematical modeling","volume":"124","author":"De Lange","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105122_bib0018","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1124\/dmd.111.038778","article-title":"Species independence in brain tissue binding using brain homogenates","volume":"39","author":"Di","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.105122_bib0019","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/dmd.107.017434","article-title":"In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system","volume":"36","author":"Feng","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.105122_bib0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/clpt.2008.195","article-title":"Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug","volume":"85","author":"Fenner","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105122_bib0021","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.110.035998","article-title":"Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods","volume":"39","author":"Friden","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.105122_bib0022","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1007\/s10557-011-6357-x","article-title":"Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist, tolvaptan","volume":"1","author":"Furukawa","year":"2011","journal-title":"Cardiovasc Drugs Ther 25 Suppl"},{"key":"10.1016\/j.ejps.2019.105122_bib0023","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-017-3383-9","article-title":"Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers","author":"Gerisch","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105122_bib0024","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1208\/s12248-007-9000-9","article-title":"The pharmacokinetics and interactions of ivermectin in humans\u2013a mini-review","volume":"10","author":"Gonzalez Canga","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2019.105122_bib0025","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s11095-007-9502-2","article-title":"On the rate and extent of drug delivery to the brain","volume":"25","author":"Hammarlund-Udenaes","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105122_bib0026","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1021\/acsmedchemlett.6b00005","article-title":"Discovery of clinical development candidate GDC-0084, a brain penetrant inhibitor of PI3K and mTOR","volume":"7","author":"Heffron","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2019.105122_bib0027","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","article-title":"Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties","volume":"158","author":"Hegedus","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105122_bib0028","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.954","article-title":"A dual-administration microtracer technique to characterize the absorption, distribution, metabolism, and excretion of [14 C]Seletalisib (UCB5857) in healthy subjects","author":"Helmer","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105122_bib0029","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-017-2205-7","article-title":"First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kdelta inhibitor for the treatment of immune and inflammatory diseases","author":"Helmer","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105122_bib0030","first-page":"24","article-title":"The vesicular transport assay: validated in vitro methods to study drug-mediated inhibition of canalicular efflux transporters ABCB11\/BSEP and ABCC2\/MRP2","volume":"23","author":"Heredi-Szabo","year":"2012","journal-title":"Curr. Protoc. Toxicol."},{"key":"10.1016\/j.ejps.2019.105122_bib0031","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1124\/dmd.107.018176","article-title":"In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier","volume":"36","author":"Hsiao","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.105122_bib0032","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1124\/jpet.105.097931","article-title":"Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data","volume":"317","author":"Hsiao","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2019.105122_bib0033","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/mp200563a","article-title":"P-glycoprotein-based loperamide-cyclosporine drug interaction at the rat blood-brain barrier: prediction from in vitro studies and extrapolation to humans","volume":"9","author":"Hsiao","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2019.105122_bib0034","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/cpt.1265","article-title":"Response to \"Impact of acute alcohol exposure on P-Glycoprotein function at the blood-brain barrier assessed using (11) C-Metoclopramide pet imaging\"","volume":"105","author":"Hsin","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105122_bib0035","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejps.2018.06.022","article-title":"Interspecies comparison of putative ligand binding sites of human, rat and mouse P-glycoprotein","volume":"122","author":"Jain","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105122_bib0036","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/j.ddtec.2014.03.011","article-title":"In vitro methods in drug transporter interaction assessment","volume":"12","author":"Jani","year":"2014","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejps.2019.105122_bib0037","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/jcph.495","article-title":"Clinical drug interaction profile of idelalisib in healthy subjects","volume":"55","author":"Jin","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105122_bib0038","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/clpt.2013.34","article-title":"Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position","volume":"94","author":"Kalvass","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105122_bib0039","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2165\/00003088-199019040-00002","article-title":"Clinical pharmacokinetics of mefloquine","volume":"19","author":"Karbwang","year":"1990","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2019.105122_bib0040","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/jps.20686","article-title":"Kinetic analyses for species differences in P-glycoprotein-mediated drug transport","volume":"95","author":"Katoh","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105122_bib0041","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejps.2005.11.011","article-title":"Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein","volume":"27","author":"Keogh","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105122_bib0042","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/bcp.12368","article-title":"Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers","volume":"78","author":"Kim","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105122_bib0043","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2019.105122_bib0044","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1124\/dmd.113.053769","article-title":"In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2\/IC50 threshold","volume":"42","author":"Kishimoto","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.105122_bib0045","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s11095-008-9678-0","article-title":"Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells","volume":"25","author":"Li","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105122_bib0046","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1124\/dmd.114.058685","article-title":"Modulation of P-glycoprotein at the human blood-brain barrier by quinidine or rifampin treatment: a positron emission tomography imaging study","volume":"43","author":"Liu","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.105122_bib0047","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/CAD.0000000000000600","article-title":"Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer","volume":"29","author":"Lopez Brunso","year":"2018","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejps.2019.105122_bib0048","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.vascn.2012.02.002","article-title":"Determining P-glycoprotein-drug interactions: evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers","volume":"65","author":"Melchior","year":"2012","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejps.2019.105122_bib0049","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ijpharm.2012.05.028","article-title":"Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp\/Abcb1) and breast cancer resistance protein (Bcrp1\/Abcg2) mediated efflux with m-TOR inhibitors","volume":"434","author":"Minocha","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2019.105122_bib0050","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/358425","article-title":"Docking applied to the prediction of the affinity of compounds to P-glycoprotein","volume":"2014","author":"Palestro","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ejps.2019.105122_bib0051","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02392-16","article-title":"Evaluation of para-Aminosalicylic acid as a substrate of multiple solute carrier uptake transporters and possible drug interactions with nonsteroidal anti-inflammatory drugs in vitro","volume":"61","author":"Parvez","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2019.105122_bib0052","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1021\/acs.jmedchem.6b01821","article-title":"Discovery of a phosphoinositide 3-Kinase (PI3K) beta\/delta inhibitor for the treatment of phosphatase and tensin homolog (PTEN) deficient tumors: building PI3Kbeta potency in a PI3Kdelta-Selective template by targeting nonconserved asp856","volume":"60","author":"Perreault","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2019.105122_bib0053","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1124\/dmd.107.018374","article-title":"The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions","volume":"36","author":"Polli","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.105122_bib0054","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2967\/jnumed.115.164350","article-title":"Imaging the impact of the P-Glycoprotein (ABCB1) function on the brain kinetics of metoclopramide","volume":"57","author":"Pottier","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejps.2019.105122_bib0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10822-013-9650-x","article-title":"In silico model for P-glycoprotein substrate prediction: insights from molecular dynamics and in vitro studies","volume":"27","author":"Prajapati","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejps.2019.105122_bib0056","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40262-015-0304-0","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of idelalisib","volume":"55","author":"Ramanathan","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2019.105122_bib0057","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.xphs.2017.04.022","article-title":"A critical view on in vitro analysis of P-glycoprotein (P-gp) transport kinetics","volume":"106","author":"Saaby","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105122_bib0058","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1124\/dmd.116.071423","article-title":"Brain distribution and efficacy of the brain penetrant PI3K inhibitor GDC-0084 in orthotopic mouse models of human glioblastoma","volume":"44","author":"Salphati","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.105122_bib0059","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1021\/jm021012t","article-title":"Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery","volume":"46","author":"Schwab","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2019.105122_bib0060","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0925-4439(96)00065-8","article-title":"Mutually co-operative interactions between modulators of P-glycoprotein","volume":"1360","author":"Shao","year":"1997","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejps.2019.105122_bib0061","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/0091270010376193","article-title":"In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects","volume":"51","author":"Shoaf","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105122_bib0062","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40268-016-0133-0","article-title":"Pharmacokinetic interaction of rifampicin with oral versus intravenous anticancer drugs: challenges, dilemmas and paradoxical effects due to multiple mechanisms","volume":"16","author":"Srinivas","year":"2016","journal-title":"Drugs R. D."},{"key":"10.1016\/j.ejps.2019.105122_bib0063","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1067\/mcp.2002.129304","article-title":"Population pharmacokinetics of tacrolimus in adult kidney transplant recipients","volume":"72","author":"Staatz","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105122_bib0064","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1124\/dmd.108.024745","article-title":"Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport","volume":"37","author":"Syvanen","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2019.105122_bib0065","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10822-016-9905-4","article-title":"Structural insights of a PI3K\/mTOR dual inhibitor with the morpholino-triazine scaffold","volume":"30","author":"Takeda","year":"2016","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejps.2019.105122_bib0066","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1007\/s11095-006-0285-7","article-title":"Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1","volume":"23","author":"Takeuchi","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105122_bib0067","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.208","article-title":"Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib","volume":"87","author":"Tanaka","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105122_bib0068","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1023\/A:1016140429238","article-title":"Are mdck cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?","volume":"19","author":"Tang","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105122_bib0069","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2967\/jnumed.118.219972","article-title":"Impact of P-Glycoprotein function on the brain kinetics of the weak substrate (11)C-Metoclopramide assessed with pet imaging in humans","volume":"60","author":"Tournier","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejps.2019.105122_bib0070","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1124\/jpet.111.184200","volume":"339","author":"Uchida","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2019.105122_bib0071","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1124\/jpet.114.214536","article-title":"Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys","volume":"350","author":"Uchida","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2019.105122_bib0072","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/17460441.2016.1101064","article-title":"Transporter assays as useful in vitro tools in drug discovery and development","volume":"11","author":"Volpe","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejps.2019.105122_bib0073","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2967\/jnumed.109.063289","article-title":"A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET","volume":"50","author":"Wagner","year":"2009","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejps.2019.105122_bib0074","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1021\/acs.molpharmaceut.5b00168","article-title":"Factors governing P-Glycoprotein-Mediated drug-drug interactions at the blood-brain barrier measured with positron emission tomography","volume":"12","author":"Wanek","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2019.105122_bib0075","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1023\/A:1016066609489","article-title":"The binding of cyclosporin a to human plasma: an in vitro microdialysis study","volume":"13","author":"Yang","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105122_bib0076","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1002\/jps.22566","article-title":"Substrate- and species-dependent inhibition of P-glycoprotein-mediated transport: implications for predicting in vivo drug interactions.","volume":"100","author":"Zolnerciks","year":"2011","journal-title":"J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719303951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719303951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:49:43Z","timestamp":1760528983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098719303951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":75,"alternative-id":["S0928098719303951"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105122","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105122"}}